{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T20:44:07Z","timestamp":1792701847200,"version":"4.5.0"},"reference-count":152,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,4,20]],"date-time":"2021-04-20T00:00:00Z","timestamp":1618876800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,4,20]],"date-time":"2021-04-20T00:00:00Z","timestamp":1618876800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1007\/s40263-021-00812-1","type":"journal-article","created":{"date-parts":[[2021,4,20]],"date-time":"2021-04-20T16:21:12Z","timestamp":1618935672000},"page":"507-526","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Is Adjunct Aripiprazole Effective in Treating Hyperprolactinemia Induced by Psychotropic Medication? A Narrative Review"],"prefix":"10.1007","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4530-7933","authenticated-orcid":false,"given":"Frank M. C.","family":"Besag","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1983-3531","authenticated-orcid":false,"given":"Michael J.","family":"Vasey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iffah","family":"Salim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,20]]},"reference":[{"issue":"4","key":"812_CR1","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1152\/physrev.2000.80.4.1523","volume":"80","author":"ME Freeman","year":"2000","unstructured":"Freeman ME, Kanyicska B, Lerant A, Nagy G. Prolactin: structure, function, and regulation of secretion. Physiol Rev. 2000;80(4):1523\u2013631.","journal-title":"Physiol Rev"},{"issue":"6","key":"812_CR2","doi-asserted-by":"publisher","first-page":"A465","DOI":"10.1016\/j.autrev.2011.11.009","volume":"11","author":"S Shelly","year":"2012","unstructured":"Shelly S, Boaz M, Orbach H. Prolactin and autoimmunity. Autoimmun Rev. 2012;11(6):A465\u201370.","journal-title":"Autoimmun Rev"},{"issue":"2_suppl","key":"812_CR3","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1177\/0269216307087148","volume":"22","author":"P Fitzgerald","year":"2008","unstructured":"Fitzgerald P, Dinan TG. Prolactin and dopamine: what is the connection? A review article. J Psychopharmacol. 2008;22(2_suppl):12\u20139.","journal-title":"J Psychopharmacol."},{"issue":"6","key":"812_CR4","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1080\/07853890410033892","volume":"36","author":"J Harris","year":"2004","unstructured":"Harris J, Stanford PM, Oakes SR, Ormandy CJ. Prolactin and the prolactin receptor: new targets of an old hormone. Ann Med. 2004;36(6):414\u201325.","journal-title":"Ann Med"},{"issue":"6","key":"812_CR5","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1210\/edrv.22.6.0451","volume":"22","author":"N Ben-Jonathan","year":"2001","unstructured":"Ben-Jonathan N, Hnasko R. Dopamine as a prolactin (PRL) inhibitor. Endocr Rev. 2001;22(6):724\u201363.","journal-title":"Endocr Rev"},{"key":"812_CR6","volume-title":"The pituitary","author":"S Melmed","year":"2010","unstructured":"Melmed S. The pituitary. New York: Academic Press; 2010."},{"issue":"2_suppl","key":"812_CR7","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1177\/0269881107087346","volume":"22","author":"RC Peveler","year":"2008","unstructured":"Peveler RC, Branford D, Citrome L, Fitzgerald P, Harvey PW, Holt RI, et al. Antipsychotics and hyperprolactinaemia: clinical recommendations. J Psychopharmacol. 2008;22(2_suppl):98\u2013103.","journal-title":"J Psychopharmacol."},{"issue":"1","key":"812_CR8","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s12991-017-0166-y","volume":"16","author":"E Kirino","year":"2017","unstructured":"Kirino E. Serum prolactin levels and sexual dysfunction in patients with schizophrenia treated with antipsychotics: comparison between aripiprazole and other atypical antipsychotics. Ann Gen Psychiatry. 2017;16(1):43.","journal-title":"Ann Gen Psychiatry"},{"issue":"4","key":"812_CR9","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1089\/cap.2008.0120","volume":"19","author":"Y Roke","year":"2009","unstructured":"Roke Y, van Harten PN, Boot AM, Buitelaar JK. Antipsychotic medication in children and adolescents: a descriptive review of the effects on prolactin level and associated side effects. J Child Adolesc Psychopharmacol. 2009;19(4):403\u201314.","journal-title":"J Child Adolesc Psychopharmacol."},{"issue":"11","key":"812_CR10","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.4088\/JCP.v65n1108","volume":"65","author":"J Montgomery","year":"2004","unstructured":"Montgomery J, Winterbottom E, Jessani M, Kohegyi E, Fulmer J, Seamonds B, et al. Prevalence of hyperprolactinemia in schizophrenia: association with typical and atypical antipsychotic treatment. J Clin Psychiatry. 2004;65(11):1491\u20138.","journal-title":"J Clin Psychiatry."},{"issue":"6","key":"812_CR11","first-page":"959","volume":"38","author":"J Cook","year":"1992","unstructured":"Cook J, Hicks J, Godwin I, Bailey J, Soldin S. Pediatric reference ranges for prolactin. Clin Chem. 1992;38(6):959.","journal-title":"Clin Chem."},{"issue":"5","key":"812_CR12","first-page":"421","volume":"28","author":"J Peuskens","year":"2014","unstructured":"Peuskens J, Pani L, Detraux J, De Hert M. The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review. CNS Drugs. 2014;28(5):421\u201353.","journal-title":"CNS Drugs"},{"issue":"2 Suppl","key":"812_CR13","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1177\/0269881107087373","volume":"22","author":"L Citrome","year":"2008","unstructured":"Citrome L. Current guidelines and their recommendations for prolactin monitoring in psychosis. J Psychopharmacol. 2008;22(2 Suppl):90\u20137.","journal-title":"J Psychopharmacol"},{"issue":"21","key":"812_CR14","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1056\/NEJMcp025334","volume":"349","author":"JA Schlechte","year":"2003","unstructured":"Schlechte JA. Clinical practice Prolactinoma. N Engl J Med. 2003;349(21):2035\u201341.","journal-title":"N Engl J Med."},{"issue":"4","key":"812_CR15","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1258\/acb.2010.010025","volume":"47","author":"CJ Bushe","year":"2010","unstructured":"Bushe CJ, Bradley A, Pendlebury J. A review of hyperprolactinaemia and severe mental illness: are there implications for clinical biochemistry? Ann Clin Biochem. 2010;47(4):292\u2013300.","journal-title":"Ann Clin Biochem"},{"issue":"6","key":"812_CR16","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1097\/jcp.0b013e31815ac4e5","volume":"27","author":"M Byerly","year":"2007","unstructured":"Byerly M, Suppes T, Tran Q-V, Baker RA. Clinical implications of antipsychotic-induced hyperprolactinemia in patients with schizophrenia spectrum or bipolar spectrum disorders: recent developments and current perspectives. J Clin Psychopharmacol. 2007;27(6):639\u201361.","journal-title":"J Clin Psychopharmacol"},{"issue":"3","key":"812_CR17","doi-asserted-by":"publisher","first-page":"163","DOI":"10.3109\/10401230209147453","volume":"14","author":"M Hamner","year":"2002","unstructured":"Hamner M. The effects of atypical antipsychotics on serum prolactin levels. Ann Clin Psychiatry. 2002;14(3):163\u201373.","journal-title":"Ann Clin Psychiatry"},{"issue":"9","key":"812_CR18","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1016\/S0024-3205(02)01775-7","volume":"71","author":"AM Meaney","year":"2002","unstructured":"Meaney AM, O\u2019Keane V. Prolactin and schizophrenia: clinical consequences of hyperprolactinaemia. Life Sci. 2002;71(9):979\u201392.","journal-title":"Life Sci"},{"issue":"3","key":"812_CR19","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s00737-002-0002-4","volume":"5","author":"JH Zhang-Wong","year":"2002","unstructured":"Zhang-Wong JH, Seeman MV. Antipsychotic drugs, menstrual regularity and osteoporosis risk. Arch Womens Ment Health. 2002;5(3):93\u20138.","journal-title":"Arch Womens Ment Health"},{"key":"812_CR20","doi-asserted-by":"publisher","first-page":"S67","DOI":"10.1016\/S0920-9964(98)00158-3","volume":"35","author":"RG Petty","year":"1999","unstructured":"Petty RG. Prolactin and antipsychotic medications: mechanism of action. Schizophr Res. 1999;35:S67\u201373.","journal-title":"Schizophr Res"},{"key":"812_CR21","volume-title":"A literature review of \"Prolactin in Schizophrenia\"","author":"J Peuskens","year":"1997","unstructured":"Peuskens J. A literature review of \u201cProlactin in Schizophrenia.\u201d Cambridge: AstraZeneca; 1997."},{"issue":"4","key":"812_CR22","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1093\/clinchem\/46.4.551","volume":"46","author":"AH Garde","year":"2000","unstructured":"Garde AH, Hansen ASM, Skovgaard LT, Christensen JM. Seasonal and biological variation of blood concentrations of total cholesterol, dehydroepiandrosterone sulfate, hemoglobin A1C, IGA, prolactin, and free testosterone in healthy women. Clin Chem. 2000;46(4):551\u20139.","journal-title":"Clin Chem."},{"issue":"2","key":"812_CR23","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/0165-1781(88)90046-7","volume":"25","author":"PJ Brown","year":"1988","unstructured":"Brown PJ, Cleghorn JM, Brown GM, Kaplan RD, Mitton J, Szechtman H, et al. Seasonal variations in prolactin levels in Schizophrenia. Psychiatry Res. 1988;25(2):157\u201362.","journal-title":"Psychiatry Res"},{"issue":"2","key":"812_CR24","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1210\/jc.2010-1692","volume":"96","author":"S Melmed","year":"2011","unstructured":"Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA, et al. Diagnosis and treatment of hyperprolactinemia: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(2):273\u201388.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2_suppl","key":"812_CR25","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1177\/0269881107088435","volume":"22","author":"C Bushe","year":"2008","unstructured":"Bushe C, Shaw M, Peveler RC. A review of the association between antipsychotic use and hyperprolactinaemia. J Psychopharmacol. 2008;22(2_suppl):46\u201355.","journal-title":"J Psychopharmacol."},{"issue":"20","key":"812_CR26","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.2165\/00003495-200464200-00003","volume":"64","author":"PM Haddad","year":"2004","unstructured":"Haddad PM, Wieck A. Antipsychotic-induced hyperprolactinaemia. Drugs. 2004;64(20):2291\u2013314.","journal-title":"Drugs"},{"issue":"Suppl 4","key":"812_CR27","first-page":"56","volume":"63","author":"GA Maguire","year":"2002","unstructured":"Maguire GA. Prolactin elevation with antipsychotic medications: mechanisms of action and clinical consequences. J Clin Psychiatry. 2002;63(Suppl 4):56\u201362.","journal-title":"J Clin Psychiatry."},{"issue":"1","key":"812_CR28","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1186\/1471-244X-13-214","volume":"13","author":"DL Kelly","year":"2013","unstructured":"Kelly DL, Wehring HJ, Earl AK, Sullivan KM, Dickerson FB, Feldman S, et al. Treating symptomatic hyperprolactinemia in women with schizophrenia: presentation of the ongoing DAAMSEL clinical trial (Dopamine partial Agonist, Aripiprazole, for the Management of Symptomatic ELevated prolactin). BMC Psychiatry. 2013;13(1):214.","journal-title":"BMC Psychiatry"},{"issue":"6","key":"812_CR29","doi-asserted-by":"publisher","first-page":"761","DOI":"10.4088\/JCP.v66n0614","volume":"66","author":"K Melkersson","year":"2005","unstructured":"Melkersson K. Differences in prolactin elevation and related symptoms of atypical antipsychotics in schizophrenic patients. J Clin Psychiatry. 2005;66(6):761\u20137.","journal-title":"J Clin Psychiatry."},{"issue":"2","key":"812_CR30","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1097\/00004714-200204000-00002","volume":"22","author":"S Smith","year":"2002","unstructured":"Smith S, Wheeler MJ, Murray R, O\u2019Keane V. The effects of antipsychotic-induced hyperprolactinaemia on the hypothalamic-pituitary-gonadal axis. J Clin Psychopharmacol. 2002;22(2):109\u201314.","journal-title":"J Clin Psychopharmacol"},{"key":"812_CR31","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1196\/annals.1429.030","volume":"1135","author":"H Joffe","year":"2008","unstructured":"Joffe H, Hayes FJ. Menstrual cycle dysfunction associated with neurologic and psychiatric disorders: their treatment in adolescents. Ann N Y Acad Sci. 2008;1135:219\u201329.","journal-title":"Ann N Y Acad Sci."},{"issue":"3","key":"812_CR32","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.psyneuen.2005.08.010","volume":"31","author":"DL Kelly","year":"2006","unstructured":"Kelly DL, Conley RR. A randomized double-blind 12-week study of quetiapine, risperidone or fluphenazine on sexual functioning in people with schizophrenia. Psychoneuroendocrinology. 2006;31(3):340\u20136.","journal-title":"Psychoneuroendocrinology"},{"issue":"8","key":"812_CR33","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1097\/00005053-198208000-00004","volume":"170","author":"AM Ghadirian","year":"1982","unstructured":"Ghadirian AM, Chouinard G, Annable L. Sexual dysfunction and plasma prolactin levels in neuroleptic-treated schizophrenic outpatients. J Nervous Mental Dis. 1982;170(8):463\u20137.","journal-title":"J Nervous Mental Dis."},{"issue":"1","key":"812_CR34","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1017\/S1461145706007115","volume":"10","author":"M Paulzen","year":"2007","unstructured":"Paulzen M, Gr\u00fcnder G. Amisulpride-induced hyperprolactinaemia is not reversed by addition of aripiprazole. Int J Neuropsychopharmacol. 2007;10(1):149\u201351.","journal-title":"Int J Neuropsychopharmacol."},{"issue":"4","key":"812_CR35","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1016\/S0022-5347(17)38964-4","volume":"142","author":"MP Leonard","year":"1989","unstructured":"Leonard MP, Nickel CJ, Morales A. Hyperprolactinemia and Impotence: why, when and how to Investigate. J Urol. 1989;142(4):992\u20134.","journal-title":"J Urol"},{"issue":"5_suppl","key":"812_CR36","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1177\/0269881112442016","volume":"26","author":"J Cookson","year":"2012","unstructured":"Cookson J, Hodgson R, Wildgust HJ. Prolactin, hyperprolactinaemia and antipsychotic treatment: a review and lessons for treatment of early psychosis. J Psychopharmacol. 2012;26(5_suppl):42\u201351.","journal-title":"J Psychopharmacol."},{"issue":"1","key":"812_CR37","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1080\/10401230500464687","volume":"18","author":"JM Meyer","year":"2006","unstructured":"Meyer JM, Lehman D. Bone mineral density in male schizophrenia patients: a review. Ann Clin Psychiatry. 2006;18(1):43\u20138.","journal-title":"Ann Clin Psychiatry"},{"issue":"9","key":"812_CR38","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.4088\/JCP.v67n0909","volume":"67","author":"D-U Jung","year":"2006","unstructured":"Jung D-U, Conley RR, Kelly DL, Kim D-W, Yoon S-H, Jang J-H, et al. Prevalence of bone mineral density loss in Korean patients with schizophrenia: a cross-sectional study. J Clin Psychiatry. 2006;67(9):1391\u20136.","journal-title":"J Clin Psychiatry."},{"issue":"26","key":"812_CR39","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1056\/NEJM198012253032605","volume":"303","author":"A Klibanski","year":"1980","unstructured":"Klibanski A, Neer RM, Beitins IZ, Ridgway EC, Zervas NT, McArthur JW. Decreased bone density in hyperprolactinemic women. N Engl J Med. 1980;303(26):1511\u20134.","journal-title":"N Engl J Med"},{"issue":"1","key":"812_CR40","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.schres.2007.01.013","volume":"93","author":"AM Meaney","year":"2007","unstructured":"Meaney AM, O\u2019Keane V. Bone mineral density changes over a year in young females with schizophrenia: relationship to medication and endocrine variables. Schizophr Res. 2007;93(1):136\u201343.","journal-title":"Schizophr Res"},{"issue":"6","key":"812_CR41","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1192\/bjp.184.6.503","volume":"184","author":"AM Meaney","year":"2004","unstructured":"Meaney AM, Smith S, Howes OD, O\u2019Brien M, Murray RM, O\u2019Keane V. Effects of long-term prolactin-raising antipsychotic medication on bone mineral density in patients with schizophrenia. Br J Psychiatry. 2004;184(6):503\u20138.","journal-title":"Br J Psychiatry"},{"issue":"2","key":"812_CR42","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1002\/hup.2387","volume":"29","author":"M Wang","year":"2014","unstructured":"Wang M, Hou R, Jian J, Mi G, Qiu H, Cao B, et al. Effects of antipsychotics on bone mineral density and prolactin levels in patients with schizophrenia: a 12-month prospective study. Hum Psychopharmacol Clin Exp. 2014;29(2):183\u20139.","journal-title":"Hum Psychopharmacol Clin Exp"},{"issue":"1","key":"812_CR43","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S0920-9964(01)00321-8","volume":"59","author":"G Abraham","year":"2003","unstructured":"Abraham G, Halbreich U, Friedman RH, Josiassen RC. Bone mineral density and prolactin associations in patients with chronic schizophrenia. Schizophr Res. 2003;59(1):17\u20138.","journal-title":"Schizophr Res."},{"issue":"1","key":"812_CR44","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1097\/01.jcp.0000150223.31007.e0","volume":"25","author":"V O'Keane","year":"2005","unstructured":"O\u2019Keane V, Meaney AM. Antipsychotic drugs: a new risk factor for osteoporosis in young women with schizophrenia? J Clin Psychopharmacol. 2005;25(1):26\u201331.","journal-title":"J Clin Psychopharmacol"},{"key":"812_CR45","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1192\/bjp.bp.106.023671","volume":"190","author":"L Howard","year":"2007","unstructured":"Howard L, Kirkwood G, Leese M. Risk of hip fracture in patients with a history of schizophrenia. Br J Psychiatry J Mental Sci. 2007;190:129\u201334.","journal-title":"Br J Psychiatry J Mental Sci."},{"issue":"7","key":"812_CR46","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1093\/jnci\/91.7.629","volume":"91","author":"SE Hankinson","year":"1999","unstructured":"Hankinson SE, Willett WC, Michaud DS, Manson JE, Colditz GA, Longcope C, et al. Plasma prolactin levels and subsequent risk of breast cancer in postmenopausal women. J Natl Cancer Inst. 1999;91(7):629\u201334.","journal-title":"J Natl Cancer Inst"},{"issue":"18","key":"812_CR47","doi-asserted-by":"publisher","first-page":"6814","DOI":"10.1158\/0008-5472.CAN-04-1870","volume":"64","author":"SS Tworoger","year":"2004","unstructured":"Tworoger SS, Eliassen AH, Rosner B, Sluss P, Hankinson SE. Plasma prolactin concentrations and risk of postmenopausal breast cancer. Can Res. 2004;64(18):6814\u20139.","journal-title":"Can Res"},{"issue":"2","key":"812_CR48","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.canlet.2006.01.032","volume":"243","author":"SS Tworoger","year":"2006","unstructured":"Tworoger SS, Hankinson SE. Prolactin and breast cancer risk. Cancer Lett. 2006;243(2):160\u20139.","journal-title":"Cancer Lett"},{"issue":"4","key":"812_CR49","doi-asserted-by":"publisher","first-page":"2476","DOI":"10.1158\/0008-5472.CAN-05-3369","volume":"66","author":"SS Tworoger","year":"2006","unstructured":"Tworoger SS, Sluss P, Hankinson SE. Association between plasma prolactin concentrations and risk of breast cancer among predominately premenopausal women. Can Res. 2006;66(4):2476\u201382.","journal-title":"Can Res"},{"issue":"12","key":"812_CR50","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1200\/JCO.2006.07.6356","volume":"25","author":"SS Tworoger","year":"2007","unstructured":"Tworoger SS, Eliassen AH, Sluss P, Hankinson SE. A prospective study of plasma prolactin concentrations and risk of premenopausal and postmenopausal breast cancer. J Clin Oncol. 2007;25(12):1482\u20138.","journal-title":"J Clin Oncol"},{"issue":"2_suppl","key":"812_CR51","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1177\/0269881107082624","volume":"22","author":"PW Harvey","year":"2008","unstructured":"Harvey PW, Everett DJ, Springall CJ. Adverse effects of prolactin in rodents and humans: breast and prostate cancer. J Psychopharmacol. 2008;22(2_suppl):20\u20137.","journal-title":"J Psychopharmacol."},{"issue":"2","key":"812_CR52","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1159\/000067769","volume":"64","author":"K Yamazawa","year":"2003","unstructured":"Yamazawa K, Matsui H, Seki K, Sekiya S. A case-control study of endometrial cancer after antipsychotics exposure in premenopausal women. Oncology. 2003;64(2):116\u201323.","journal-title":"Oncology"},{"issue":"10","key":"812_CR53","doi-asserted-by":"publisher","first-page":"830","DOI":"10.3109\/00048674.2011.589044","volume":"45","author":"WJ Inder","year":"2011","unstructured":"Inder WJ, Castle D. Antipsychotic-induced hyperprolactinaemia. Aust N Z J Psychiatry. 2011;45(10):830\u20137.","journal-title":"Aust N Z J Psychiatry"},{"issue":"4","key":"812_CR54","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1002\/hup.1116","volume":"25","author":"S Madhusoodanan","year":"2010","unstructured":"Madhusoodanan S, Parida S, Jimenez C. Hyperprolactinemia associated with psychotropics\u2014a review. Hum Psychopharmacol Clin Exp. 2010;25(4):281\u201397.","journal-title":"Hum Psychopharmacol Clin Exp"},{"issue":"9896","key":"812_CR55","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","volume":"382","author":"S Leucht","year":"2013","unstructured":"Leucht S, Cipriani A, Spineli L, Mavridis D, \u00d6rey D, Richter F, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382(9896):951\u201362.","journal-title":"Lancet"},{"issue":"1","key":"812_CR56","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1176\/appi.ajp.159.1.133","volume":"159","author":"P Turrone","year":"2002","unstructured":"Turrone P, Kapur S, Seeman MV, Flint AJ. Elevation of prolactin levels by atypical antipsychotics. Am J Psychiatry. 2002;159(1):133\u20135.","journal-title":"Am J Psychiatry"},{"key":"812_CR57","first-page":"2076","volume":"2","author":"S Melmed","year":"2005","unstructured":"Melmed S. Disorders of the anterior pituitary and hypothalamus. Harrison\u2019s Princ Intern Med. 2005;2:2076\u201397.","journal-title":"Harrison's Princ Intern Med."},{"issue":"8","key":"812_CR58","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.4065\/80.8.1050","volume":"80","author":"ME Molitch","year":"2005","unstructured":"Molitch ME. Medication-induced hyperprolactinemia. Mayo Clin Proc. 2005;80(8):1050\u20137.","journal-title":"Mayo Clin Proc"},{"issue":"3","key":"812_CR59","doi-asserted-by":"publisher","first-page":"261","DOI":"10.3109\/10398561003686763","volume":"18","author":"M Skopek","year":"2010","unstructured":"Skopek M, Manoj P. Hyperprolactinaemia during treatment with paliperidone. Australas Psychiatry. 2010;18(3):261\u20133.","journal-title":"Australas Psychiatry"},{"key":"812_CR60","first-page":"S248","volume":"8","author":"J Hellewell","year":"1998","unstructured":"Hellewell J, Cantillon M. Antipsychotic tolerability: the attitudes and perceptions of medical professionals, patients and caregivers towards the side effects of antipsychotic therapy. Eur Neuropsychopharmacol. 1998;8:S248.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"2","key":"812_CR61","doi-asserted-by":"publisher","first-page":"179","DOI":"10.2165\/11585350-000000000-00000","volume":"71","author":"G Masi","year":"2011","unstructured":"Masi G, Liboni F. Management of schizophrenia in children and adolescents. Drugs. 2011;71(2):179\u2013208.","journal-title":"Drugs"},{"issue":"Suppl 4","key":"812_CR62","first-page":"26","volume":"69","author":"CU Correll","year":"2008","unstructured":"Correll CU. Assessing and maximizing the safety and tolerability of antipsychotics used in the treatment of children and adolescents. J Clin Psychiatry. 2008;69(Suppl 4):26\u201336.","journal-title":"J Clin Psychiatry."},{"issue":"Suppl 6","key":"812_CR63","first-page":"20","volume":"65","author":"BJ McConville","year":"2004","unstructured":"McConville BJ, Sorter MT. Treatment challenges and safety considerations for antipsychotic use in children and adolescents with psychoses. J Clin Psychiatry. 2004;65(Suppl 6):20\u20139.","journal-title":"J Clin Psychiatry."},{"issue":"3","key":"812_CR64","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1089\/cap.2004.14.350","volume":"14","author":"E Saito","year":"2004","unstructured":"Saito E, Correll CU, Gallelli K, McMeniman M, Parikh UH, Malhotra AK, et al. A prospective study of hyperprolactinemia in children and adolescents treated with atypical antipsychotic agents. J Child Adolesc Psychopharmacol. 2004;14(3):350\u20138.","journal-title":"J Child Adolesc Psychopharmacol."},{"issue":"1","key":"812_CR65","doi-asserted-by":"publisher","first-page":"159402","DOI":"10.1186\/1687-9856-2010-159402","volume":"2010","author":"AL Rosenbloom","year":"2010","unstructured":"Rosenbloom AL. Hyperprolactinemia with antipsychotic drugs in children and adolescents. Int J Pediatr Endocrinol. 2010;2010(1):159402.","journal-title":"Int J Pediatr Endocrinol"},{"issue":"4","key":"812_CR66","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1136\/adc.2004.053553","volume":"90","author":"JH Davies","year":"2005","unstructured":"Davies JH, Evans BAJ, Gregory JW. Bone mass acquisition in healthy children. Arch Dis Child. 2005;90(4):373\u20138.","journal-title":"Arch Dis Child"},{"issue":"12","key":"812_CR67","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1517\/14656566.4.12.2259","volume":"4","author":"M Gitlin","year":"2003","unstructured":"Gitlin M. Sexual dysfunction with psychotropic drugs. Expert Opin Pharmacother. 2003;4(12):2259\u201369.","journal-title":"Expert Opin Pharmacother"},{"issue":"4","key":"812_CR68","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1080\/00926230390195524","volume":"29","author":"KP Rosenberg","year":"2003","unstructured":"Rosenberg KP, Bleiberg KL, Koscis J, Gross C. A survey of sexual side effects among severely mentally ill patients taking psychotropic medications: impact on compliance. J Sex Marital Ther. 2003;29(4):289\u201396.","journal-title":"J Sex Marital Ther"},{"issue":"12","key":"812_CR69","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.4088\/JCP.v63n1206","volume":"63","author":"DO Perkins","year":"2002","unstructured":"Perkins DO. Predictors of noncompliance in patients with schizophrenia. J Clin Psychiatry. 2002;63(12):1121\u20138.","journal-title":"J Clin Psychiatry."},{"issue":"s382","key":"812_CR70","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/j.1600-0447.1994.tb05859.x","volume":"89","author":"W Fleischhacker","year":"1994","unstructured":"Fleischhacker W, Meise U, G\u00fcnther V, Kurz M. Compliance with antipsychotic drug treatment: influence of side effects. Acta Psychiatr Scand. 1994;89(s382):11\u20135.","journal-title":"Acta Psychiatr Scand"},{"key":"812_CR71","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1093\/oso\/9780192622839.003.0009","volume":"1","author":"TR Barnes","year":"1993","unstructured":"Barnes TR, Harvey CA. Psychiatric drugs and sexuality. Sexual Pharmacol. 1993;1:176\u201396.","journal-title":"Sexual Pharmacol"},{"issue":"4","key":"812_CR72","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1017\/S0033291700036539","volume":"20","author":"SE Finn","year":"1990","unstructured":"Finn SE, Bailey JM, Schultz RT, Faber R. Subjective utility ratings of neuroleptics in treating schizophrenia. Psychol Med. 1990;20(4):843\u20138.","journal-title":"Psychol Med"},{"issue":"9","key":"812_CR73","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1007\/s40263-015-0278-3","volume":"29","author":"A de Bartolomeis","year":"2015","unstructured":"de Bartolomeis A, Tomasetti C, Iasevoli F. Update on the mechanism of action of aripiprazole: translational insights into antipsychotic strategies beyond dopamine receptor antagonism. CNS Drugs. 2015;29(9):773\u201399.","journal-title":"CNS Drugs"},{"key":"812_CR74","doi-asserted-by":"publisher","first-page":"251","DOI":"10.2165\/00023210-200418040-00005","volume":"18","author":"J Liberman","year":"2004","unstructured":"Liberman J. Dopamine partial agonists: a new class of antipsychotic drugs in patients with chronic schizophrenia. CNS Drugs. 2004;18:251\u201367.","journal-title":"CNS Drugs"},{"issue":"1","key":"812_CR75","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.rasd.2012.08.001","volume":"7","author":"D Cohen","year":"2013","unstructured":"Cohen D, Raffin M, Canitano R, Bodeau N, Bonnot O, P\u00e9risse D, et al. Risperidone or aripiprazole in children and adolescents with autism and\/or intellectual disability: a Bayesian meta-analysis of efficacy and secondary effects. Res Autism Spectr Disord. 2013;7(1):167\u201375.","journal-title":"Res Autism Spectr Disord."},{"issue":"1","key":"812_CR76","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1744-859X-8-16","volume":"8","author":"KN Fountoulakis","year":"2009","unstructured":"Fountoulakis KN, Vieta E. Efficacy and safety of aripiprazole in the treatment of bipolar disorder: a systematic review. Ann Gen Psychiatry. 2009;8(1):16.","journal-title":"Ann Gen Psychiatry"},{"issue":"4","key":"812_CR77","doi-asserted-by":"publisher","first-page":"427","DOI":"10.2147\/nedt.2006.2.4.427","volume":"2","author":"L Citrome","year":"2006","unstructured":"Citrome L. A review of aripiprazole in the treatment of patients with schizophrenia or bipolar I disorder. Neuropsychiatr Dis Treat. 2006;2(4):427\u201343.","journal-title":"Neuropsychiatr Dis Treat."},{"issue":"9","key":"812_CR78","doi-asserted-by":"publisher","first-page":"571","DOI":"10.2217\/pgs-2020-0024","volume":"21","author":"D Koller","year":"2020","unstructured":"Koller D, Abad-Santos F. The pharmacogenetics of aripiprazole-induced hyperprolactinemia: what do we know? Pharmacogenomics. 2020;21(9):571\u20134.","journal-title":"Pharmacogenomics"},{"issue":"7","key":"812_CR79","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.eurpsy.2007.03.002","volume":"22","author":"R Kerwin","year":"2007","unstructured":"Kerwin R, Millet B, Herman E, Banki CM, Lublin H, Pans M, et al. A multicentre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients Schizophrenia Trial of Aripiprazole: (STAR) study. Eur Psychiatry. 2007;22(7):433\u201343.","journal-title":"Eur Psychiatry"},{"issue":"1","key":"812_CR80","doi-asserted-by":"publisher","first-page":"30","DOI":"10.2174\/1872214807666131229125700","volume":"8","author":"D De Berardis","year":"2014","unstructured":"De Berardis D, Fornaro M, Serroni N, Marini S, Piersanti M, Cavuto M, et al. Treatment of antipsychotic-induced hyperprolactinemia: an update on the role of the dopaminergic receptors D2 partial agonist aripiprazole. Recent Pat Endocr Metab Immune Drug Discov. 2014;8(1):30\u20137.","journal-title":"Recent Pat Endocr Metab Immune Drug Discov"},{"issue":"1","key":"812_CR81","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1124\/jpet.102.033175","volume":"302","author":"KD Burris","year":"2002","unstructured":"Burris KD, Molski TF, Xu C, Ryan E, Tottori K, Kikuchi T, et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther. 2002;302(1):381\u20139.","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"812_CR82","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1097\/JCP.0000000000001158","volume":"40","author":"T Sugai","year":"2020","unstructured":"Sugai T, Suzuki Y, Yamazaki M, Sugawara N, Yasui-Furukori N, Shimoda K, et al. Lower prolactin levels in patients treated with aripiprazole regardless of antipsychotic monopharmacy or polypharmacy. J Clin Psychopharmacol. 2020;40(1):14\u20137.","journal-title":"J Clin Psychopharmacol"},{"issue":"4","key":"812_CR83","first-page":"PCC.13l01519","volume":"15","author":"DL Boggs","year":"2013","unstructured":"Boggs DL, Ranganathan M, Boggs AA, Bihday CM, Peluse BE, D\u2019Souza DC. Treatment of hyperprolactinemia and gynecomastia with adjunctive aripiprazole in 2 men receiving long-acting injectable antipsychotics. Prim Care Companion CNS Disord. 2013;15(4):PCC.13l01519.","journal-title":"Prim Care Companion CNS Disord."},{"issue":"1","key":"812_CR84","doi-asserted-by":"publisher","first-page":"S164","DOI":"10.1186\/1744-859X-9-S1-S164","volume":"9","author":"P Kotorki","year":"2010","unstructured":"Kotorki P, Pelka P, Leotsakou C, Kalogeropoulou A, Fiste M, Vagionis G, et al. Reversal of symptomatic antipsychotic-induced hyperprolactinemia with addition of aripiprazole. Ann Gen Psychiatry. 2010;9(1):S164.","journal-title":"Ann Gen Psychiatry"},{"issue":"5","key":"812_CR85","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1097\/JCP.0b013e31814f4d5d","volume":"27","author":"RA Lorenz","year":"2007","unstructured":"Lorenz RA, Weinstein B. Resolution of haloperidol-induced hyperprolactinemia with aripiprazole. J Clin Psychopharmacol. 2007;27(5):524\u20135.","journal-title":"J Clin Psychopharmacol"},{"issue":"2","key":"812_CR86","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1111\/j.1365-2710.2007.00806.x","volume":"32","author":"J Wolf","year":"2007","unstructured":"Wolf J, Fiedler U. Hyperprolactinemia and amenorrhea associated with olanzapine normalized after addition of aripiprazole. J Clin Pharm Ther. 2007;32(2):197\u20138.","journal-title":"J Clin Pharm Ther"},{"issue":"8","key":"812_CR87","doi-asserted-by":"publisher","first-page":"1542-a-3","DOI":"10.1176\/appi.ajp.162.8.1542-a","volume":"162","author":"R Wahl","year":"2005","unstructured":"Wahl R, Ostroff R. Reversal of symptomatic hyperprolactinemia by aripiprazole. Am J Psychiatry. 2005;162(8):1542-a-3.","journal-title":"Am J Psychiatry."},{"issue":"S1","key":"812_CR88","first-page":"105","volume":"29","author":"S \u00d6nen","year":"2019","unstructured":"\u00d6nen S. Add-on aripiprazole treatment for atypical antipsychotic-induced hyperprolactinemia in female schizophrenic patients: preliminary findings of a 12-week follow-up study. Klinik Psikofarmakoloji Bulteni. 2019;29(S1):105\u20136.","journal-title":"Klinik Psikofarmakoloji Bulteni."},{"issue":"10","key":"812_CR89","doi-asserted-by":"publisher","first-page":"e0139717-e","DOI":"10.1371\/journal.pone.0139717","volume":"10","author":"J Zhao","year":"2015","unstructured":"Zhao J, Song X, Ai X, Gu X, Huang G, Li X, et al. Adjunctive aripiprazole treatment for risperidone-induced hyperprolactinemia: an 8-week randomized, open-label, comparative clinical trial. PLoS ONE. 2015;10(10):e0139717-e.","journal-title":"PLoS ONE"},{"issue":"6","key":"812_CR90","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1097\/WNF.0000000000000175","volume":"39","author":"HW Yoon","year":"2016","unstructured":"Yoon HW, Lee JS, Park SJ, Lee S-K, Choi W-J, Kim TY, et al. Comparing the effectiveness and safety of the addition of and switching to aripiprazole for resolving antipsychotic-induced hyperprolactinemia: a multicenter, open-label, prospective study. Clin Neuropharmacol. 2016;39(6):288\u201394.","journal-title":"Clin Neuropharmacol"},{"issue":"4","key":"812_CR91","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1097\/JCP.0b013e3182970431","volume":"33","author":"M Ziadi Trives","year":"2013","unstructured":"Ziadi Trives M, Bonete Ll\u00e1cer J-M, Garc\u00eda Escudero M-A, Mart\u00ednez Pastor CJ. Effect of the addition of aripiprazole on hyperprolactinemia associated with risperidone long-acting injection. J Clin Psychopharmacol. 2013;33(4):538\u201341.","journal-title":"J Clin Psychopharmacol"},{"issue":"8","key":"812_CR92","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1016\/j.pnpbp.2010.08.012","volume":"34","author":"C-K Chen","year":"2010","unstructured":"Chen C-K, Huang Y-S, Ree S-C, Hsiao C-C. Differential add-on effects of aripiprazole in resolving hyperprolactinemia induced by risperidone in comparison to benzamide antipsychotics. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34(8):1495\u20139.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"812_CR93","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5234\/cnpt.1.1","volume":"1","author":"K Mihara","year":"2010","unstructured":"Mihara K, Nagai G, Nakamura A, Fukuji Y, Suzuki T, Kondo T. Improvement in antipsychotic-induced hyperprolactinemia with the addition of aripiprazole in schizophrenic patients. Clin Neuropsychopharmacol Ther. 2010;1:1\u20135.","journal-title":"Clin Neuropsychopharmacol Ther."},{"issue":"5","key":"812_CR94","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1097\/JCP.0b013e3181ee832d","volume":"30","author":"N Yasui-Furukori","year":"2010","unstructured":"Yasui-Furukori N, Furukori H, Sugawara N, Fujii A, Kaneko S. Dose-dependent effects of adjunctive treatment with aripiprazole on hyperprolactinemia induced by risperidone in female patients with schizophrenia. J Clin Psychopharmacol. 2010;30(5):596\u20139.","journal-title":"J Clin Psychopharmacol"},{"issue":"1","key":"812_CR95","doi-asserted-by":"publisher","first-page":"38","DOI":"10.4103\/IJPSYM.IJPSYM_147_17","volume":"40","author":"D Raveendranthan","year":"2018","unstructured":"Raveendranthan D, Rao NP, Rao MG, Mangot AG, Varambally S, Kesavan M, et al. Add-on aripiprazole for atypical antipsychotic-induced, clinically significant hyperprolactinemia. Indian J Psychol Med. 2018;40(1):38\u201340.","journal-title":"Indian J Psychol Med."},{"issue":"3","key":"812_CR96","first-page":"42","volume":"2","author":"LE Shores","year":"2005","unstructured":"Shores LE. Normalization of risperidone-induced hyperprolactinemia with the addition of aripiprazole. Psychiatry (Edgmont). 2005;2(3):42\u20135.","journal-title":"Psychiatry (Edgmont)"},{"key":"812_CR97","first-page":"549","volume":"11","author":"F Ranjbar","year":"2015","unstructured":"Ranjbar F, Sadeghi-Bazargani H, Niari Khams P, Arfaie A, Salari A, Farahbakhsh M. Adjunctive treatment with aripiprazole for risperidone-induced hyperprolactinemia. Neuropsychiatr Dis Treat. 2015;11:549\u201355.","journal-title":"Neuropsychiatr Dis Treat."},{"key":"812_CR98","unstructured":"The Cochrane Collaboration. Data collection form for intervention reviews. 2014."},{"key":"812_CR99","volume-title":"The Maudsley prescribing guidelines in psychiatry","author":"DM Taylor","year":"2018","unstructured":"Taylor DM, Barnes TR, Young AH. The Maudsley prescribing guidelines in psychiatry. 13th ed. New York: Wiley; 2018.","edition":"13"},{"issue":"4","key":"812_CR100","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1097\/JCP.0000000000000898","volume":"38","author":"DL Kelly","year":"2018","unstructured":"Kelly DL, Powell MM, Wehring HJ, Sayer MA, Kearns AM, Hackman AL, et al. Adjunct aripiprazole reduces prolactin and prolactin-related adverse effects in premenopausal women with psychosis: results from the DAAMSEL clinical trial. J Clin Psychopharmacol. 2018;38(4):317\u201326.","journal-title":"J Clin Psychopharmacol"},{"key":"812_CR101","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.psyneuen.2015.04.011","volume":"58","author":"J-X Chen","year":"2015","unstructured":"Chen J-X, Su Y-A, Bian Q-T, Wei L-H, Zhang R-Z, Liu Y-H, et al. Adjunctive aripiprazole in the treatment of risperidone-induced hyperprolactinemia: a randomized, double-blind, placebo-controlled, dose\u2013response study. Psychoneuroendocrinology. 2015;58:130\u201340.","journal-title":"Psychoneuroendocrinology"},{"issue":"2","key":"812_CR102","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1192\/bjpo.bp.115.001248","volume":"1","author":"G Raghuthaman","year":"2015","unstructured":"Raghuthaman G, Venkateswaran R, Krishnadas R. Adjunctive aripiprazole in risperidone-induced hyperprolactinaemia: double-blind, randomised, placebo-controlled trial. BJPsych Open. 2015;1(2):172\u20137.","journal-title":"BJPsych Open."},{"issue":"2","key":"812_CR103","doi-asserted-by":"publisher","first-page":"60","DOI":"10.9758\/cpn.2013.11.2.60","volume":"11","author":"BJ Lee","year":"2013","unstructured":"Lee BJ, Lee SJ, Kim MK, Lee JG, Park SW, Kim GM, et al. Effect of aripiprazole on cognitive function and hyperprolactinemia in patients with schizophrenia treated with risperidone. Clin Psychopharmacol Neurosci. 2013;11(2):60\u20136.","journal-title":"Clin Psychopharmacol Neurosci."},{"issue":"10","key":"812_CR104","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.4088\/JCP.09m05154yel","volume":"70","author":"JM Kane","year":"2009","unstructured":"Kane JM, Correll CU, Goff DC, Kirkpatrick B, Marder SR, Vester-Blokland E, et al. A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy. J Clin Psychiatry. 2009;70(10):1348\u201357.","journal-title":"J Clin Psychiatry."},{"issue":"9","key":"812_CR105","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1176\/appi.ajp.2007.06071075","volume":"164","author":"J-C Shim","year":"2007","unstructured":"Shim J-C, Shin J-GK, Kelly DL, Jung D-U, Seo Y-S, Liu K-H, et al. Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial. Am J Psychiatry. 2007;164(9):1404\u201310.","journal-title":"Am J Psychiatry."},{"key":"812_CR106","doi-asserted-by":"publisher","unstructured":"Yeager A, Shad MU. Aripiprazole for the management of antipsychotic-induced hyperprolactinemia a retrospective case series. Prim Care Companion CNS Disord. 2020;22(1):19br02536. https:\/\/doi.org\/10.4088\/PCC.19br02536","DOI":"10.4088\/PCC.19br02536"},{"key":"812_CR107","first-page":"186","volume":"29","author":"M Aydin","year":"2019","unstructured":"Aydin M. Improvement of paliperidone palmitate-induced hyperprolactinemia with the addition of aripiprazole: a case report. Klinik Psikofarmakoloji Bulteni. 2019;29:186.","journal-title":"Klinik Psikofarmakoloji Bulteni."},{"key":"812_CR108","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.jad.2019.03.006","volume":"250","author":"T Luo","year":"2019","unstructured":"Luo T, Liu Q-S, Yang Y-J, Wei B. Aripiprazole for the treatment of duloxetine-induced hyperprolactinemia: a case report. J Affect Disord. 2019;250:330\u20132.","journal-title":"J Affect Disord."},{"issue":"4","key":"812_CR109","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1080\/24750573.2018.1468617","volume":"28","author":"U \u015eermin Bilgen","year":"2018","unstructured":"\u015eermin Bilgen U, Hamza A. Hyperprolactinaemia and menstrual irregularity emerging in association with risperidone use and treated with aripiprazole in an adolescent diagnosed with schizophrenia: a case report. Psychiatry Clin Psychopharmacol. 2018;28(4):469\u201372.","journal-title":"Psychiatry Clin Psychopharmacol."},{"key":"812_CR110","first-page":"238","volume":"28","author":"N Yazar","year":"2018","unstructured":"Yazar N, Atao\u011flu A, \u00d6z\u00e7etin A, \u00d6lmez SB, Kocag\u00f6z ZB, \u00c7avdar M. Low-dose ariripiprazole use in hyperprolactinemia caused by paliperidone palmitate: a case report. Klinik Psikofarmakoloji Bulteni. 2018;28:238.","journal-title":"Klinik Psikofarmakoloji Bulteni."},{"key":"812_CR111","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.2147\/NDT.S167129","volume":"14","author":"P Zhi","year":"2018","unstructured":"Zhi P, Wang Y, Quan W, Su Y, Zhang H. Aripiprazole combination for reversal of paliperidone-induced increase in prolactin level. Neuropsychiatr Dis Treat. 2018;14:2175\u20139.","journal-title":"Neuropsychiatr Dis Treat."},{"key":"812_CR112","first-page":"124","volume":"27","author":"Y \u00c7ok\u00fcnl\u00fc","year":"2017","unstructured":"\u00c7ok\u00fcnl\u00fc Y, Ayd\u0131n M, Elmas T\u015e, Eren \u0130. Improvement of haloperidol decanoate-induced hyperprolactinemia with aripiprazole in a patient with schizophrenia. Klinik Psikofarmakoloji Bulteni. 2017;27:124.","journal-title":"Klinik Psikofarmakoloji Bulteni."},{"key":"812_CR113","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.ajp.2016.10.005","volume":"25","author":"K Naono-Nagatomo","year":"2017","unstructured":"Naono-Nagatomo K, Naono H, Abe H, Takeda R, Funahashi H, Uchimura D, et al. Partial regimen replacement with aripiprazole reduces serum prolactin in patients with a long history of schizophrenia: a case series. Asian J Psychiatr. 2017;25:36\u201341.","journal-title":"Asian J Psychiatr"},{"key":"812_CR114","first-page":"135","volume":"27","author":"EN Sungur","year":"2017","unstructured":"Sungur EN, Kenar AN\u0130. Effect of the addition of long-acting injectable aripiprazole on risperidone long-acting injection-induced hyperprolactinemia. Klinik Psikofarmakoloji Bulteni. 2017;27:135.","journal-title":"Klinik Psikofarmakoloji Bulteni."},{"key":"812_CR115","unstructured":"Viroja P, Iqbal T, Hussain S, Grimes D. Use of aripiprazole in hyperprolactinemia. J Pakistan Psychiatr Soc. 2015;12(1):47\u201348."},{"issue":"3","key":"812_CR116","doi-asserted-by":"publisher","first-page":"253","DOI":"10.5455\/bcp.20131213042842","volume":"24","author":"G Alpak","year":"2014","unstructured":"Alpak G, Unal A, Bulbul F, Aksoy I, Demir B, Savas HA. Hyperprolactinemia due to paliperidone palmitate and treatment with aripiprazole. Klinik Psikofarmakoloji B\u00fclteni-Bull Clin Psychopharmacol. 2014;24(3):253\u20136.","journal-title":"Klinik Psikofarmakoloji B\u00fclteni-Bull Clin Psychopharmacol."},{"issue":"5","key":"812_CR117","first-page":"290","volume":"40","author":"N Basterreche","year":"2012","unstructured":"Basterreche N, Zumarraga M, Arrue A, Olivas O, Davila W. Aripiprazole reverses paliperidone-induced hyperprolactinemia. Actas espanolas de psiquiatria. 2012;40(5):290\u20132.","journal-title":"Actas espanolas de psiquiatria."},{"issue":"1","key":"812_CR118","doi-asserted-by":"publisher","first-page":"58","DOI":"10.4103\/0253-7613.62398","volume":"42","author":"A Aggarwal","year":"2010","unstructured":"Aggarwal A, Jain M, Garg A, Jiloha RC. Aripiprazole for olanzapine-induced symptomatic hyper prolactinemia. Indian J Pharmacol. 2010;42(1):58\u20139.","journal-title":"Indian J Pharmacol."},{"issue":"5","key":"812_CR119","first-page":"PCC.13l01544","volume":"15","author":"MF Gwynette","year":"2013","unstructured":"Gwynette MF, Evangelidis N. Treating symptomatic hyperprolactinemia secondary to a long-acting injectable atypical antipsychotic in a patient with bipolar disorder due to an anoxic brain injury. Prim Care Companion CNS Disord. 2013;15(5):PCC.13l01544.","journal-title":"Prim Care Companion CNS Disord."},{"key":"812_CR120","unstructured":"WHO Expert Committee on Biological Standardization. WHO Expert Committee on Biological Standardization (Meeting held in Geneva from 11 to 19 October 1988): Thirty-ninth Report: World Health Organization; Geneva, 1989."},{"issue":"8","key":"812_CR121","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1016\/j.pnpbp.2008.09.016","volume":"32","author":"M-L Lu","year":"2008","unstructured":"Lu M-L, Shen WW, Chen C-H. Time course of the changes in antipsychotic-induced hyperprolactinemia following the switch to aripiprazole. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(8):1978\u201381.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"5","key":"812_CR122","doi-asserted-by":"publisher","first-page":"e100091-e","DOI":"10.1136\/gpsych-2019-100091","volume":"32","author":"W Zheng","year":"2019","unstructured":"Zheng W, Cai D-B, Yang X-H, Ungvari GS, Ng CH, Shi Z-M, et al. Adjunctive aripiprazole for antipsychotic-related hyperprolactinaemia in patients with first-episode schizophrenia: a meta-analysis. Gen Psychiatr. 2019;32(5):e100091-e.","journal-title":"Gen Psychiatr."},{"issue":"1","key":"812_CR123","first-page":"4","volume":"27","author":"M Meng","year":"2015","unstructured":"Meng M, Li W, Zhang S, Wang H, Sheng J, Wang J, et al. Using aripiprazole to reduce antipsychotic-induced hyperprolactinemia: meta-analysis of currently available randomized controlled trials. Shanghai Arch Psychiatry. 2015;27(1):4\u201317.","journal-title":"Shanghai Arch Psychiatry."},{"key":"812_CR124","doi-asserted-by":"crossref","unstructured":"Li X, Tang Y, Wang C. Adjunctive aripiprazole versus placebo for antipsychotic-induced hyperprolactinemia: meta-analysis of randomized controlled trials. PLoS One. 2013;8(8):e70179-e.","DOI":"10.1371\/journal.pone.0070179"},{"key":"812_CR125","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.schres.2020.04.031","volume":"222","author":"J Labad","year":"2020","unstructured":"Labad J, Montalvo I, Gonz\u00e1lez-Rodr\u00edguez A, Garc\u00eda-Rizo C, Crespo-Facorro B, Monreal JA, et al. Pharmacological treatment strategies for lowering prolactin in people with a psychotic disorder and hyperprolactinaemia: a systematic review and meta-analysis. Schizophr Res. 2020;222:88\u201396.","journal-title":"Schizophr Res"},{"key":"812_CR126","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.psychres.2015.12.033","volume":"237","author":"Y Qiao","year":"2016","unstructured":"Qiao Y, Yang F, Li C, Guo Q, Wen H, Zhu S, et al. Add-on effects of a low-dose aripiprazole in resolving hyperprolactinemia induced by risperidone or paliperidone. Psychiatry Res. 2016;237:83\u20139.","journal-title":"Psychiatry Res"},{"issue":"1","key":"812_CR127","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1097\/00004714-199902000-00011","volume":"19","author":"DL Kleinberg","year":"1999","unstructured":"Kleinberg DL, Davis JM, de Coster R, Van Baelen B, Brecher M. Prolactin levels and adverse events in patients treated with risperidone. J Clin Psychopharmacol. 1999;19(1):57\u201361.","journal-title":"J Clin Psychopharmacol"},{"issue":"6","key":"812_CR128","first-page":"575","volume":"169","author":"O Serri","year":"2003","unstructured":"Serri O, Chik CL, Ur E, Ezzat S. Diagnosis and management of hyperprolactinemia. Can Med Assoc J. 2003;169(6):575\u201381.","journal-title":"Can Med Assoc J"},{"issue":"7","key":"812_CR129","doi-asserted-by":"publisher","first-page":"761","DOI":"10.4088\/JCP.v64n0704","volume":"64","author":"D Becker","year":"2003","unstructured":"Becker D, Liver O, Mester R, Rapoport M, Weizman A, Weiss M. Risperidone, but not olanzapine, decreases bone mineral density in female premenopausal schizophrenia patients. J Clin Psychiatry. 2003;64(7):761\u20136.","journal-title":"J Clin Psychiatry."},{"issue":"3","key":"812_CR130","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1192\/bjp.182.3.199","volume":"182","author":"A Wieck","year":"2003","unstructured":"Wieck A, Haddad PM. Antipsychotic-induced hyperprolactinaemia in women: pathophysiology, severity and consequences: selective literature review. Br J Psychiatry. 2003;182(3):199\u2013204.","journal-title":"Br J Psychiatry"},{"issue":"3","key":"812_CR131","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1111\/j.1600-0447.1995.tb09758.x","volume":"91","author":"U Wesselmann","year":"1995","unstructured":"Wesselmann U, Windgassen K. Galactorrhea: subjective response by schizophrenic patients. Acta Psychiatr Scand. 1995;91(3):152\u20135.","journal-title":"Acta Psychiatr Scand"},{"key":"812_CR132","unstructured":"Bazire S. Psychotropic Drug Directory 2018: The Professionals' Pocket Handbook and Aide Memoire. Lloyd-Reinhold Communications; 2018."},{"issue":"22","key":"812_CR133","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.1007\/s00213-017-4730-6","volume":"234","author":"J Grigg","year":"2017","unstructured":"Grigg J, Worsley R, Thew C, Gurvich C, Thomas N, Kulkarni J. Antipsychotic-induced hyperprolactinemia: synthesis of world-wide guidelines and integrated recommendations for assessment, management and future research. Psychopharmacology. 2017;234(22):3279\u201397.","journal-title":"Psychopharmacology"},{"issue":"5","key":"812_CR134","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1177\/0269881110391123","volume":"25","author":"TR Barnes","year":"2011","unstructured":"Barnes TR, Schizophrenia Consensus Group of the British Association for Psychopharmacology. Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2011;25(5):567\u2013620.","journal-title":"J Psychopharmacol."},{"key":"812_CR135","volume-title":"Clinical Guideline [CG178] Psychosis and schizophrenia in adults: prevention and management","author":"National Institute for Health and Care Excellence (NICE)","year":"2014","unstructured":"National Institute for Health and Care Excellence (NICE). Clinical Guideline [CG178] Psychosis and schizophrenia in adults: prevention and management. London: NICE; 2014."},{"issue":"1","key":"812_CR136","doi-asserted-by":"publisher","first-page":"2","DOI":"10.3109\/15622975.2012.739708","volume":"14","author":"A Hasan","year":"2013","unstructured":"Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. World J Biol Psychiatry. 2013;14(1):2\u201344.","journal-title":"World J Biol Psychiatry."},{"issue":"3","key":"812_CR137","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.rpsmen.2016.06.001","volume":"9","author":"\u00c1L Montejo","year":"2016","unstructured":"Montejo \u00c1L, Arango C, Bernardo M, Carrasco JL, Crespo-Facorro B, Cruz JJ, et al. Spanish consensus on the risks and detection of antipsychotic drug-related hyperprolactinaemia. Revista de Psiquiatr\u00eda y Salud Mental (English Edition). 2016;9(3):158\u201373.","journal-title":"Revista de Psiquiatr\u00eda y Salud Mental (English Edition)."},{"key":"812_CR138","volume-title":"The Maudsley prescribing guidelines in psychiatry","author":"DM Taylor","year":"2015","unstructured":"Taylor DM, Paton C, Kapur S. The Maudsley prescribing guidelines in psychiatry. 12th ed. New York: Wiley; 2015.","edition":"12"},{"issue":"1","key":"812_CR139","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/0269881119889296","volume":"34","author":"TR Barnes","year":"2020","unstructured":"Barnes TR, Drake R, Paton C, Cooper SJ, Deakin B, Ferrier IN, et al. Evidence-based guidelines for the pharmacological treatment of schizophrenia: updated recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2020;34(1):3\u201378.","journal-title":"J Psychopharmacol"},{"issue":"4","key":"812_CR140","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/j.1600-0447.2006.00897.x","volume":"115","author":"J Eberhard","year":"2007","unstructured":"Eberhard J, Lindstr\u00f6m E, Holstad M, Levander S. Prolactin level during 5 years of risperidone treatment in patients with psychotic disorders. Acta Psychiatr Scand. 2007;115(4):268\u201376.","journal-title":"Acta Psychiatr Scand"},{"issue":"11","key":"812_CR141","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.4088\/JCP.v64n1113","volume":"64","author":"RL Findling","year":"2003","unstructured":"Findling RL, Kusumakar V, Daneman D, Moshang T, De Smedt G, Binder C. Prolactin levels during long-term risperidone treatment in children and adolescents. J Clin Psychiatry. 2003;64(11):1362\u20139.","journal-title":"J Clin Psychiatry."},{"issue":"1\u20132","key":"812_CR142","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.jad.2008.11.003","volume":"116","author":"M Tohen","year":"2009","unstructured":"Tohen M, Sutton VK, Calabrese JR, Sachs GS, Bowden CL. Maintenance of response following stabilization of mixed index episodes with olanzapine monotherapy in a randomized, double-blind, placebo-controlled study of bipolar 1 disorder. J Affect Disord. 2009;116(1\u20132):43\u201350.","journal-title":"J Affect Disord"},{"key":"812_CR143","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.yfrne.2017.02.003","volume":"45","author":"\u00c1L Montejo","year":"2017","unstructured":"Montejo \u00c1L, Arango C, Bernardo M, Carrasco JL, Crespo-Facorro B, Cruz JJ, et al. Multidisciplinary consensus on the therapeutic recommendations for iatrogenic hyperprolactinemia secondary to antipsychotics. Front Neuroendocrinol. 2017;45:25\u201334.","journal-title":"Front Neuroendocrinol"},{"key":"812_CR144","doi-asserted-by":"publisher","first-page":"S108","DOI":"10.1016\/j.euroneuro.2008.02.004","volume":"18","author":"AL Montejo","year":"2008","unstructured":"Montejo AL. Prolactin awareness: An essential consideration for physical health in schizophrenia. Eur Neuropsychopharmacol. 2008;18:S108\u201314.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"8","key":"812_CR145","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1176\/appi.ajp.161.8.1334","volume":"161","author":"SR Marder","year":"2004","unstructured":"Marder SR, Essock SM, Miller AL, Buchanan RW, Casey DE, Davis JM, et al. Physical health monitoring of patients with schizophrenia. Am J Psychiatry. 2004;161(8):1334\u201349.","journal-title":"Am J Psychiatry"},{"issue":"5","key":"812_CR146","doi-asserted-by":"publisher","first-page":"408","DOI":"10.4088\/JCP.v63n0506","volume":"63","author":"K-S Kim","year":"2002","unstructured":"Kim K-S, Pae C-U, Chae J-H, Bahk W-M, Jun T-Y, Kim D-J, et al. Effects of olanzapine on prolactin levels of female patients with schizophrenia treated with risperidone. J Clin Psychiatry. 2002;63(5):408\u201313.","journal-title":"J Clin Psychiatry."},{"issue":"4","key":"812_CR147","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1177\/026988110101500408","volume":"15","author":"PM Haddad","year":"2001","unstructured":"Haddad PM, Hellewell JSE, Wieck A. Antipsychotic induced hyperprolactinaemia: a series of illustrative case reports. J Psychopharmacol. 2001;15(4):293\u20135.","journal-title":"J Psychopharmacol"},{"issue":"4","key":"812_CR148","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1517\/14740338.2012.683523","volume":"11","author":"JA Gallego","year":"2012","unstructured":"Gallego JA, Nielsen J, De Hert M, Kane JM, Correll CU. Safety and tolerability of antipsychotic polypharmacy. Expert Opin Drug Saf. 2012;11(4):527\u201342.","journal-title":"Expert Opin Drug Saf"},{"issue":"5","key":"812_CR149","doi-asserted-by":"publisher","first-page":"383","DOI":"10.2165\/11587810-000000000-00000","volume":"25","author":"TRE Barnes","year":"2011","unstructured":"Barnes TRE, Paton C. Antipsychotic polypharmacy in schizophrenia. CNS Drugs. 2011;25(5):383\u201399.","journal-title":"CNS Drugs"},{"issue":"9","key":"812_CR150","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1176\/appi.ps.55.9.1006","volume":"55","author":"L Citrome","year":"2004","unstructured":"Citrome L, Jaffe A, Levine J, Allingham B, Robinson J. Relationship between antipsychotic medication treatment and new cases of diabetes among psychiatric inpatients. Psychiatr Serv. 2004;55(9):1006\u201313.","journal-title":"Psychiatr Serv"},{"issue":"6","key":"812_CR151","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.endonu.2012.11.005","volume":"60","author":"I Halperin Rabinovich","year":"2013","unstructured":"Halperin Rabinovich I, C\u00e1mara G\u00f3mez R, Garc\u00eda Mouriz M, Ollero G-A. Gu\u00eda cl\u00ednica de diagn\u00f3stico y tratamiento del prolactinoma y la hiperprolactinemia. Endocrinol Nutr. 2013;60(6):308\u201319.","journal-title":"Endocrinol Nutr"},{"issue":"9","key":"812_CR152","first-page":"575","volume":"16","author":"J Ho","year":"2011","unstructured":"Ho J, Panagiotopoulos C, McCrindle B, Grisaru S, Pringsheim T, Effectiveness TCAfM, et al. Management recommendations for metabolic complications associated with second-generation antipsychotic use in children and youth. Paediatr Child Health. 2011;16(9):575\u201380.","journal-title":"Paediatr Child Health."}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-021-00812-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-021-00812-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-021-00812-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T17:39:39Z","timestamp":1724866779000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-021-00812-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,20]]},"references-count":152,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["812"],"URL":"https:\/\/doi.org\/10.1007\/s40263-021-00812-1","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,20]]},"assertion":[{"value":"26 March 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors declare that they have no competing interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest\/Competing interests"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors contributed to the preparation, drafting and revision of the manuscript. All authors read and approved the final manuscript and agree to be accountable for the work presented.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}